hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06260800, orgStudyIdInfo id: PI 23-3405, briefTitle: Spanish Version of Credibility and Expectancy Questionnaire in Patients With Musculoskeletal Injuries, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-08, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: University of Valladolid, class: OTHER, descriptionModule briefSummary: Physiotherapy treatment of musculoskeletal injuries should be performed following the main clinical guidelines of person-centered care. Patients' perception of the abilities and facilities provided by physiotherapists boost a convenient therapeutic relationship. This relation is linked with more satisfaction and adherence during the treatment, as well as credibility and expectancy of the patient related to the treatment. Thus, Credibility and Expectancy questionnaire is normally used to assess that point. CEQ presents good psychometric properties when used in Physisiotherapy interventions, but there is not a spanish version of this questionaire., conditionsModule conditions: Validation Study, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Validation CEQ, outcomesModule primaryOutcomes measure: Content validity, primaryOutcomes measure: Construct validity, primaryOutcomes measure: Reliability, primaryOutcomes measure: Criterion validity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Silvia Lahuerta Martín, status: RECRUITING, city: Soria, zip: 42004, country: Spain, geoPoint lat: 41.76401, lon: -2.46883, hasResults: False
protocolSection identificationModule nctId: NCT06260787, orgStudyIdInfo id: OBGY-202401.01, briefTitle: Clinical Profiles And In Vitro Fertilization Success, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-03-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Universitas Padjadjaran, class: OTHER, descriptionModule briefSummary: This research was carried out to determine if the IVF patients' clinical profile were connected with how successful in their getting pregnant. This was a cross-sectional study which recruited all patients, performed at a major fertility clinic in Indonesia. Our data collection period spanned between January 2017 and December 2021., conditionsModule conditions: in Vitro Fertilisation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 223, type: ACTUAL, armsInterventionsModule interventions name: In Vitro Fertilisation, outcomesModule primaryOutcomes measure: Pregnancy rate, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, city: Bandung, state: Jawa Barat, zip: 40161, country: Indonesia, geoPoint lat: -6.92222, lon: 107.60694, hasResults: False
protocolSection identificationModule nctId: NCT06260774, orgStudyIdInfo id: TTX-MC138-002, briefTitle: Study of TTX-MC138 in Subjects With Advanced Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2026-02-01, completionDateStruct date: 2027-02-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: TransCode Therapeutics, class: INDUSTRY, descriptionModule briefSummary: A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors, conditionsModule conditions: Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Dose Escalation Study Design, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: TTX-MC138, outcomesModule primaryOutcomes measure: Dose Escalation - Adverse Events, primaryOutcomes measure: Dose Escalation - Overall Response Rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06260748, orgStudyIdInfo id: LBI-CDCA-001, secondaryIdInfos id: 2023-505759-29-00, type: OTHER, domain: EU Clinical Trials Register, briefTitle: A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Leadiant Biosciences, Inc., class: INDUSTRY, descriptionModule briefSummary: This study is designed to demonstrate the beneficial effect of CDCA in the treatment of CTX-associated diarrhea in approximately 10 participants aged 2-75 years old with newly diagnosed CTX or suspected CTX who have never received treatment with CDCA., conditionsModule conditions: Cerebrotendinous Xanthomatoses, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Chenodeoxycholic acid, interventions name: Chenodeoxycholic acid Placebo, outcomesModule primaryOutcomes measure: Change from baseline at Week 4 in average number of stools with a BSS score of 6 or 7 per day, secondaryOutcomes measure: Change in plasma cholestanol levels from baseline to Week 12, secondaryOutcomes measure: Change in urine and/or plasma bile alcohol levels from baseline to Week 12, secondaryOutcomes measure: Incidence of, severity/intensity of, and relationship to study drug of AEs, secondaryOutcomes measure: Incidence of, severity/intensity of, and relationship to study drug of SAEs, secondaryOutcomes measure: Incidence of, severity/intensity of AESIs, secondaryOutcomes measure: Incidence of, severity/intensity of, and changes in laboratory values, secondaryOutcomes measure: Incidence of, severity/intensity of, and changes in physical examination, secondaryOutcomes measure: Incidence of, severity/intensity of, and changes in vital signs, secondaryOutcomes measure: Number of participants with discontinuations due to AEs, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06260735, orgStudyIdInfo id: HS25897 (H2023:073), secondaryIdInfos id: URGP#51472, type: OTHER_GRANT, domain: University of Manitoba, secondaryIdInfos id: RGPIN-2015-05703, type: OTHER_GRANT, domain: NSERC, briefTitle: Non-invasive Spinal Cord Stimulation After Spinal Cord Injury, acronym: SCI-ES-WALK, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-15, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: University of Manitoba, class: OTHER, descriptionModule briefSummary: Spinal cord injury (SCI) is a central nervous system injury that often leads to motor dysfunction. Non-invasive electrical stimulation of the spinal cord has been recognized as a potential method of reactivating lost spinal neural networks to improve motor recovery and exercise response after SCI. Trans-spinal electrical stimulation (ts-ES) has been found to increase functional gains in people after SCI when applied in combination with other motor training protocols.This project aims to evaluate the effects of non-invasive lumbar spinal cord electrical stimulation on the motor function of trunk and lower limbs in people with SCI after augmenting their locomotor training (treadmill stepping) with step-cycle-based electrical peripheral neural stimulation methods., conditionsModule conditions: Spinal Cord Injuries, conditions: Spinal Cord Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Trans-spinal electrical stimulation, interventions name: Electrical muscle activation, interventions name: Treadmill walking, outcomesModule primaryOutcomes measure: Neurophysiological markers or stepping, primaryOutcomes measure: Electromyography (EMG) of ankle extensor muscles, primaryOutcomes measure: Metabolic function testing, secondaryOutcomes measure: 6 Min Walk Test, secondaryOutcomes measure: SCIM-Spinal Cord Independence Measure- Mobility scores, secondaryOutcomes measure: Autonomic scores, secondaryOutcomes measure: Rate or Perceived Exertion (RPE) of Submaximal VO2 testing, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Manitoba, status: RECRUITING, city: Winnipeg, state: Manitoba, zip: R3E 0W2, country: Canada, contacts name: Katinka Stecina, role: CONTACT, phone: 204-789-3761, email: katinka.stecina@umanitoba.ca, geoPoint lat: 49.8844, lon: -97.14704, hasResults: False
protocolSection identificationModule nctId: NCT06260696, orgStudyIdInfo id: DAS-7626, secondaryIdInfos id: U1111-1282-5512, type: OTHER, domain: World Health Organization (WHO), briefTitle: Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender, acronym: ASPECT - APAC, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-10, primaryCompletionDateStruct date: 2023-10-05, completionDateStruct date: 2023-10-05, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: The purpose of this survey is to collect information for scientific research and to identify the impact of overweight and obesity on health-related quality of life., conditionsModule conditions: Overweight, conditions: Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 3000, type: ACTUAL, armsInterventionsModule interventions name: No treatment is given, outcomesModule primaryOutcomes measure: Score on IWQOL-Lite validated, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Novo Nordisk Investigational Site, city: Dubai, country: United Arab Emirates, geoPoint lat: 25.0657, lon: 55.17128, hasResults: False
protocolSection identificationModule nctId: NCT06260683, orgStudyIdInfo id: OSU-22240, secondaryIdInfos id: NCI-2023-04102, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: R01DA057327, type: NIH, link: https://reporter.nih.gov/quickSearch/R01DA057327, briefTitle: A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-29, primaryCompletionDateStruct date: 2027-04-29, completionDateStruct date: 2027-04-29, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Ohio State University Comprehensive Cancer Center, class: OTHER, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: This clinical trial compares the use of tobacco flavored electronic cigarettes (ECs) to non-tobacco flavored ECs on smoking behavior in current cigarette smokers to use of nicotine replacement therapy (patches and lozenges). ECs may reduce cigarette craving and withdrawal symptoms, increase motivation and confidence to stop cigarette smoking, and decrease cigarette smoking and dependence. By comparing participants' preferred flavor ECs (PEC) to tobacco flavor ECs (TEC) to NRT, researchers hope to determine the effect of EC flavors on appeal and use, and learn how ECs affect smoking behaviors and health., conditionsModule conditions: Cigarette Smoking-Related Carcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 1500, type: ESTIMATED, armsInterventionsModule interventions name: Nicotine Replacement, interventions name: Questionnaire Administration, interventions name: Vaping, interventions name: Vaping, outcomesModule primaryOutcomes measure: Biochemically verified 7-day point prevalence abstinence from cigarettes, primaryOutcomes measure: Switching rate, secondaryOutcomes measure: Cigarettes smoked per day, secondaryOutcomes measure: Change in nicotine dependence, secondaryOutcomes measure: Changes in cigarette craving and nicotine withdrawal, secondaryOutcomes measure: Number of days used, secondaryOutcomes measure: Product appeal, secondaryOutcomes measure: Continued purchase and use of ECs, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ohio State University Comprehensive Cancer Center, city: Columbus, state: Ohio, zip: 43210, country: United States, contacts name: Theodore L. Wagener, PhD, role: CONTACT, email: Theodore.Wagener@osumc.edu, contacts name: Theodore L. Wagener, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06260670, orgStudyIdInfo id: CP0004, briefTitle: FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation, acronym: FLOW EVAL-AF, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2022-10-28, completionDateStruct date: 2022-10-28, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Ablacon, Inc., class: INDUSTRY, descriptionModule briefSummary: FLOW EVAL-AF is a prospective, observational, single center pilot trial. The FLOW EVAL-AF trial is designed to identify driver sources in patients with persistent or longstanding persistent AF using EGF mapping and describe the activation patterns observed from concomitant high density mapping of those regions., conditionsModule conditions: Persistent Atrial Fibrillation, conditions: Longstanding Persistent Atrial Fibrillation, conditions: Atrial Fibrillation, Persistent, conditions: Arrhythmias, Cardiac, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ACTUAL, armsInterventionsModule interventions name: Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter, outcomesModule primaryOutcomes measure: Descriptive correlation of electrogram patterns, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Herz-und Diabeteszentrum NRW (Clinic of Ruhr University of Bochum), city: Bad Oeynhausen, state: North Rhine-Westphalia, zip: 32545, country: Germany, geoPoint lat: 52.20699, lon: 8.80365, hasResults: False
protocolSection identificationModule nctId: NCT06260657, orgStudyIdInfo id: 2021PI124, briefTitle: Search for Olfactory Cells Within the Fetal Ethmoid Epithelium, acronym: COEF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Central Hospital, Nancy, France, class: OTHER, descriptionModule briefSummary: The recent rhinological functional approach known as "Evo-Devo" leads us to consider the nose not as a single organ, but as the construction of a specifically olfactory organ within which functional respiratory structures have developed over the course of species evolution in the same way they develop during human embryogenesis.In adult humans, the olfactory structures are limited to two narrow regions situated at the upper part of the nasal passages known as olfactory clefts. Nevertheless, phylogenetic evidence indicates that these olfactory clefts are vestiges of an olfactory organ that once occupied the entire ethmoid bone in the front of the skull base.The hypothesis of this study posits that, during the embryological development of the ethmoid bone, it would initially be covered with olfactory mucosa, which would gradually diminish as the lateral masses of the ethmoid formed, eventually persisting exclusively within the olfactory clefts of the ethmoid by the conclusion of the first trimester (end of organogenesis). Besides their fundamental interest, the results of this study could help understand the still unknown pathogenesis of nasal polyposis, a chronic anosmic disease with a prevalence of 2 to 4% in the French and European population.This study requires a series of ethmoidal samples from human fetuses at various ages between 7 and 15 weeks of gestational age. Specific immunohistological labeling techniques under standard optical microscopy will be used to search for and quantify olfactory nerve cells within the fetal ethmoidal mucosa., conditionsModule conditions: Fetal Ethmoidal Mucosa, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Histological analysis on fetal ethmoids, outcomesModule primaryOutcomes measure: Immunohistological positive signal of primary olfactive neurons, secondaryOutcomes measure: Concentration of primary olfactory neurons immunohistological signals, eligibilityModule sex: ALL, minimumAge: 7 Weeks, maximumAge: 15 Weeks, stdAges: CHILD, contactsLocationsModule locations facility: Centre Hospitalier Régional Universitaire - Service ORL, city: Nancy, country: France, contacts name: Roger Jankowski, MD/PhD, role: CONTACT, email: r.jankowski@chru-nancy.fr, geoPoint lat: 48.68439, lon: 6.18496, hasResults: False
protocolSection identificationModule nctId: NCT06260644, orgStudyIdInfo id: Repairing defective composite, briefTitle: Evaluation of Using Self-adhering Flowable Resin Composite in Repairing Old Defective Resin Composite Restorations Over 18 Months Follow up. (A Randomized Clinical Trial), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: This research proposal is evaluating the clinical performance of using self-adhering flowable resin composite in repairing old occlusal defective resin composite versus conventional flowable resin composite restoration over 18 months., conditionsModule conditions: Occlusal Caries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: parallel assignment, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: double ( participants, outcomes assessor) participants and both assessors will be blind to the type of material used, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: VertiseTM flowable composite (Kerr,USA), outcomesModule primaryOutcomes measure: Restoration clinical performance using FDI criteria, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, city: Cairo, zip: 113311, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06260631, orgStudyIdInfo id: P.T.REC/012/004807, briefTitle: Efficacy of High-intensity Laser Acupuncture in Patients With Chronic, Non-specific Low Back Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, collaborators name: King Khalid University, descriptionModule briefSummary: The purpose of this study is to investigate the efficacy of high-intensity laser acupuncture on peak torque, power of trunk extensors and flexors, back pain, range of motion, function, and satisfaction in patients with chronic nonspecific low back pain (CNLBP)., conditionsModule conditions: Chronic Nonspecific Low-back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: high-intensity laser acupuncture and exercise therapy program, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: random generator, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: high-intensity laser acupuncture and Exercise therapy program, interventions name: Sham laser acupuncture, outcomesModule primaryOutcomes measure: peak torque, primaryOutcomes measure: peak torque, primaryOutcomes measure: Average Power, primaryOutcomes measure: Average Power, secondaryOutcomes measure: Pain Intensity, secondaryOutcomes measure: Pain Intensity, secondaryOutcomes measure: lumbar flexion and extension ROM assessment, secondaryOutcomes measure: lumbar flexion and extension ROM assessment, secondaryOutcomes measure: Disability, secondaryOutcomes measure: Disability, secondaryOutcomes measure: patient Satisfaction, secondaryOutcomes measure: patient Satisfaction, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Doaa Ayoub Elimy, status: RECRUITING, city: Giza, zip: 11251, country: Egypt, contacts name: Doaa A Elimy, lecturer, role: CONTACT, phone: 00201066474654, email: do3aayoub25@gmail.com, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False